Volume 66, Issue 3, Pages (September 2004)

Slides:



Advertisements
Similar presentations
Experimental model: Daily intra-peritoneal instillation of PD solution (Dianeal 3.86%) for 4-5 weeks via mini vascular access port (fig 1) Daily administration.
Advertisements

Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model  Siska Mortier, Dirk Faict, Norbert.
Volume 57, Issue 2, Pages (October 2000)
Volume 66, Issue 6, Pages (December 2004)
Volume 67, Issue 5, Pages (May 2005)
Buffer transport in peritoneal dialysis
Use of icodextrin in high transport ultrafiltration failure
D. Teta, M. Maillard, G. Halabi, M. Burnier  Kidney International 
Volume 62, Issue 2, Pages (August 2002)
Impact of new dialysis solutions on peritonitis rates
Volume 58, Issue 2, Pages (August 2000)
Volume 71, Issue 3, Pages (February 2007)
Smad7 gene transfer inhibits peritoneal fibrosis
Volume 68, Issue 5, Pages (November 2005)
Volume 66, Issue 6, Pages (December 2004)
Volume 65, Issue 5, Pages (May 2004)
Volume 58, Issue 6, Pages (December 2000)
Volume 62, Issue 4, Pages (October 2002)
Ho-Han Wu, Szu-Yuan Li, Wu-Chang Yang  Kidney International 
Volume 57, Issue 2, Pages (October 2000)
Volume 59, Issue 6, Pages (June 2001)
Endothelial cell dysfunction and nitric oxide synthase
Fluid overload and residual renal function in peritoneal dialysis: the proof of the pudding is in the eating  Wim Van Biesen, Achim Jörres  Kidney International 
Volume 63, Issue 1, Pages (January 2003)
Effect of advanced glycation end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells  Gloria.
Volume 60, Issue 5, Pages (November 2001)
Endothelial-derived vasoactive mediators in polycystic kidney disease
Volume 68, Issue 4, Pages (October 2005)
Volume 58, Issue 1, Pages (July 2000)
Volume 61, Issue 1, Pages (January 2002)
Glucose degradation products in peritoneal dialysis fluids: Do they harm?  Janusz Witowski, Achim Jörres, Katarzyna Korybalska, Krzysztof Ksiazek, Justyna.
Volume 62, Issue 2, Pages (August 2002)
Volume 54, Issue 2, Pages (August 1998)
The renin–angiotensin–aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum?  Sharon J. Nessim, Jeffrey.
Volume 86, Issue 6, Pages (December 2014)
Claudine S. Bonder, Lisa M. Ebert  Kidney International 
The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions  P.M. ter Wee, R.H.J. Beelen, J.
Volume 54, Issue 6, Pages (January 1998)
Volume 72, Issue 12, Pages (December 2007)
Volume 63, Issue 2, Pages (February 2003)
Volume 77, Issue 4, Pages (February 2010)
Volume 58, Issue 2, Pages (August 2000)
In vitro biocompatibility performance of Physioneal
Volume 76, Issue 6, Pages (September 2009)
Volume 68, Issue 3, Pages (September 2005)
Volume 74, Issue 6, Pages (September 2008)
Clifford J. Holmes, Dirk Faict  Kidney International 
Nephrology Crossword: Peritoneal Dialysis
Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model  Siska Mortier, Dirk Faict, Norbert.
Future of icodextrin as an osmotic agent in peritoneal dialysis
AGEs in foods: Do they play a role in uremia?
Volume 60, Issue 6, Pages (December 2001)
Volume 64, Issue 5, Pages (November 2003)
Volume 60, Issue 1, Pages (July 2001)
Volume 61, Issue 2, Pages (February 2002)
Volume 62, Issue 3, Pages (September 2002)
Volume 84, Issue 2, Pages (August 2013)
Peter G. Blake, Arsh K. Jain, Sechelle Yohanna  Kidney International 
Volume 56, Issue 6, Pages (December 1999)
Volume 63, Issue 1, Pages (January 2003)
Avshalom Shostak, Valery Wajsbrot, Lazaro Gotloib  Kidney International 
Biocompatibility of icodextrin
Quantification of free water transport in peritoneal dialysis
Volume 57, Issue 2, Pages (October 2000)
Volume 62, Issue 5, (November 2002)
Volume 72, Issue 11, Pages (December 2007)
Volume 65, Issue 1, Pages (January 2004)
The International Pediatric Peritonitis Registry: Starting to walk
Volume 65, Issue 5, Pages (May 2004)
Volume 57, Issue 1, Pages (January 2000)
Presentation transcript:

Volume 66, Issue 3, Pages 1257-1265 (September 2004) Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane  Siska Mortier, Dirk Faict, Casper G. Schalkwijk, Norbert H. Lameire, A.N.S. De Vriese  Kidney International  Volume 66, Issue 3, Pages 1257-1265 (September 2004) DOI: 10.1111/j.1523-1755.2004.00879.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Net ultrafiltration after a 120-minute dwell of 15 mL of 3.86% glucose dialysate in experimental animals exposed to the standard peritoneal dialysis fluid (PDF) (N = 10) (▪), low-glucose degradation product (GDP) bicarbonate/lactate-buffered PDF (N = 10) (▪), amino acid–based PDF (N = 9) (□), and Earle's Balanced Salt Solution (EBSS) (N = 10) (▪). *P < 0.05 vs. EBSS, low-GDP bicarbonate/lactate-buffered PDF, and amino acid–based PDF. Kidney International 2004 66, 1257-1265DOI: (10.1111/j.1523-1755.2004.00879.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Immunostaining for endothelial nitric oxide synthase (eNOS) of the visceral peritoneum. (A) Prominent eNOS staining was present after 12 weeks' exposure to standard peritoneal dialysis fluid (PDF) (×200). (B) Detail of the eNOS staining in the vascular endothelium of a standard PDF-treated rat (×630). Animals exposed to low-glucose degradation product (GDP) bicarbonate/lactate-buffered PDF (C), and amino acid–based PDF (D) showed an eNOS staining comparable to the Earle's Balanced Salt Solution (EBSS)-exposed group (E) (×200). No specific staining is observed when sections are incubated without primary antibody (F) (×200). Kidney International 2004 66, 1257-1265DOI: (10.1111/j.1523-1755.2004.00879.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Immunostaining for vascular endothelial growth factor (VEGF) staining of the visceral peritoneum. (A) VEGF staining was prominent in the mesothelial cells and vascular wall of standard peritoneal dialysis fluid (PDF)-exposed rats (×200). (B) Detail of mesothelium and blood vessel of a rat exposed to standard PDF (×630). No pronounced staining was observed in rats exposed to low-glucose degradation product (GDP) bicarbonate/lactate-buffered PDF (C), amino acid–based PDF (D), and Earle's Balanced Salt Solution (EBSS) (E) (×200). No specific staining is observed when sections are incubated without primary antibody (F) (×200). Kidney International 2004 66, 1257-1265DOI: (10.1111/j.1523-1755.2004.00879.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Picro Sirius Red staining of the visceral peritoneum. (A) Animals exposed to standard peritoneal dialysis fluid (PDF) for 12 weeks showed a prominent deposition of fibrous tissue (×200). Detail of the submesothelial fibrotic tissue in a standard PDF-treated animal (×630) (B). Almost no fibrosis was present in the animals exposed to low-glucose degradation product (GDP) bicarbonate/lactate-buffered PDF (C), amino acid–based PDF (D), and Earle's Balanced Salt Solution (EBSS) (E) (×200). Kidney International 2004 66, 1257-1265DOI: (10.1111/j.1523-1755.2004.00879.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 5 Immunostaining for methylglyoxal (MGO) adducts of the visceral peritoneum. (A) MGO adducts strongly accmulated in peritoneal tissue exposed to standard peritoneal dialysis fluid (PDF) (×200) and to a lesser extent in low-glucose degradation product (GDP) bicarbonate/lactate-buffered PDF (B) (×200). No MGO adduct accmulation was observed in animals exposed to amino acid–based PDF (C) (×200) or Earle's Balanced Salt Solution (EBSS) (D) (×200). No specific staining is observed when sections are incubated without primary antibody (E) (×200). Kidney International 2004 66, 1257-1265DOI: (10.1111/j.1523-1755.2004.00879.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 6 Immunostaining for advanced glycation end products (AGE) of the visceral peritoneum. (A) Standard peritoneal dialysis fluid (PDF) exposure resulted in AGE accmulation in peritoneal tissue (×200). Detail of AGE localization in the standard PDF-exposed blood vessels (B) and mesothelium (C) (×630). In contrast, almost no AGE accmulation was present in tissue exposed to low-glucose degradation product (GDP) bicarbonate/lactate-buffered PDF (D), amino acid-based PDF (E), and Earle's Balanced Salt Solution (EBSS) (F) (×200). No specific staining is observed when sections are incubated without primary antibody (G) (×200). Kidney International 2004 66, 1257-1265DOI: (10.1111/j.1523-1755.2004.00879.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 7 Immunostaining for receptor for advanced glycation end products (RAGE) of the visceral peritoneum. (A) RAGE staining was elevated in the standard peritoneal dialysis fluid (PDF)-exposed animals compared to the other PDF-treated groups (×200). Detail of RAGE-stained vascular tissue (B) and mesothelium (C) in a standard PDF-treated rat (×630). Low-grade staining was detected in animals treated with low-glucose degradation product (GDP) bicarbonate/lactate-buffered PDF (D) and amino acid–based PDF (E) which was significantly higher than those exposed to Earle's Balanced Salt Solution (EBSS) (F) (×200). No specific staining is observed when sections are incubated without primary antibody (G) (×200). Kidney International 2004 66, 1257-1265DOI: (10.1111/j.1523-1755.2004.00879.x) Copyright © 2004 International Society of Nephrology Terms and Conditions